Adkinskyed2851

The expression of B cell lymphoma/lewkmia-2 (bcl-2), BCL2-associated X (bax), caspase-3, α7 Nicotinic acetylcholine receptor (α-7 nR), and inhibitor of nuclear factor kappa-Bα (I-κB-α) in the myocardium was measured. C.I. Basic Blue 9 trihydrate Dexmedetomidine can significantly reduce the myocardial tissue injury induced by myocardial ischemia-reperfusion in rats. Dexmedetomidine may relieve myocardial ischemia-reperfusion injury by activating the cholinergic anti-inflammatory pathway.To investigate the clinical efficacy of targeted injection of drugs surrounding the protruded lumbar disc in combination with the ozone in treatment of lumbar disc protrusion. Between January 2017 and January 2019, a total of 120 patients with lumbar disc protrusion were recruited in this study and divided into the control group and observation group, with 60 patients in each group. Patients in the control group received the ozone treatment, while those in the observation group additionally took the targeted injection of betamethasone surrounding the protruded lumbar disc. Following one month of treatment, we compared the short-term efficacy, joint range of motion in bending forward or backward of the lumbar disc, limb function, life quality and functional disturbance before and after treatment. In the observation group, the short-term effectiveness rate was higher than that in the control group (P less then 0.05), while after treatment, the joint range of motion in bending forward or backward of lumbar disc in the observation group was improved when comparing to the control group (P less then 0.05). After treatment, BI and Fugl-Meyer scale were all higher in the observation than those in the control group (P less then 0.05), with a lower Oswestry score (P less then 0.05). Targeted injection of betamethasone surrounding the protruded lumbar disc in combination with the ozone performs well in short-term efficacy, conducive to the improvement of the lumbar disc function and limb function and alleviation in function disturbance. Thus, this strategy is worthy of being promoted in clinical practice.Twenty-four patients with cold, dampness, obstructive ankylosing spondylitis were treated with sulfasalazine and sulfasalazine in combination with moxibustion for 3 weeks. The results showed that the combined treatment of traditional Chinese and western medicine was significantly higher than those of western medicine treatment, meanwhile, the scoreofsymptoms quantification, C-reactive protein and erythrocyte sedimentation rate of the integrated Chinese and western medicine treatment were significantly lower than those of western medicine treatment, and the level of physical signs was significantly higher than that of western medicine treatment, and there were no significant differences in adverse reactions. Moxibustion combined with sulfasalazine in the treatment of cold and damp obstructive ankylosing spondylitis can effectively improve the characteristics of the body, relieve pain symptoms and improve the prognosis.Drug-resistant tuberculosis is a clinically common respiratory-borne chronic infectious disease. Fluoroquinolone drugs can inhibit the replication and transcription of bacterial DNA and cause bacteria to die, and the antibacterial spectrum of such drugs is broad, especially for Mycobacterium tuberculosis-induced diseases. This article observes and compares the clinical efficacy of levofloxacin and moxifloxacin in the treatment of multidrug-resistant tuberculosis (MDR-TB). At the end of the course of treatment, the treatment success rate was 76.4% in the control group and 68.2% in the treatment group. The difference between the two groups was not statistically significant (P0.05). For multidrug-resistant tuberculosis, levofloxacin tablets and moxifloxacin tablets have similar effects in the treatment of multidrug-resistant tuberculosis, adverse drug reactions, and economically difficult multidrug-resistant patients. Drug sensitivity indicates that they are sensitive to levofloxacin.Pediatric pneumonia and heart failure is a common critical illness in pediatrics. This article observes the clinical effects of dopamine and dobutamine in the treatment of pneumonia and heart failure. As a key neurotransmitter in the hypothalamus and pituitary gland, dopamine plays a very important role in the central nervous excitement of the human body. Dopamine could also promote excitement in the respiratory center and reduces oxygen consumption in the breath, thereby improving the symptoms of respiratory failure in children. Observe and compare the clinical efficacy of the two groups of children, the disappearance of lung rales, the time to correct heart failure and the length of hospital stay. The total effective rate in the observation group was 91%; the total effective rate in the control group was 65.4%. There was a significant difference in the total effective rate between the two groups of children. The time of disappearance of lung rales, the time of correction of heart failure and the length of hospital stay in the observation group were significantly shorter than those in the control group (P less then 0.05). The clinical effects of dopamine and dobutamine on pneumonia and heart failure are significant.This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD). In the present clinical trial, Chinese elderly patients aged ≥65 years with a confirmed diagnosis of AD were enrolled. The patients received MAO-B inhibitor (Selegiline 5 mg) or DNP 10 mg daily (reference) for 6 months. The efficacy and safety data were collected from 120 patients (60 patients in each group) every 3 weeks until 6 months. The primary endpoints were to assess the change in cognitive score from baseline in both the treatment group. The result of the present study showed that the patients treated with MAO-B inhibitor and DNP have similar efficacy and safety profile Considering the clinical benefit, mean (SD) improvement in sign and symptoms was numerically greater in DNP-treated patients as compared to MAO-B inhibitor at endpoint visit (SIB 12.3 (3.7) vs 11.3 (4.2); AD severity 14.2 (3.5); CIBIS+/CIBIC 10.2 (2.7) vs 9.4 (3.2); ADCS-ADL 14.